Green Cross Corp., of Yongin, South Korea, said the FDA accepted for review the biologics license application for IVIG-SN (human normal immunoglobulin G for intravenous administration) intended for the treatment of primary immunodeficiency diseases (PID), a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.